NanoViricides is a Phase II-ready, clinical-stage company, that is creating antiviral drugs that are effective even as variants emerge. The company is at a key inflection point in valuation with a portfolio of novel drug candidates that are designed to bind, encapsulate and destroy viruses without reliance on the patient's immune system.
The company reports that NV-387 exhibits ultra-broad antiviral activity. NV-387's spectrum extends to multiple viruses including COVID-19, coronavirus, RSV, influenza A, Mpox, smallpox, bird flu and H5N1.
In comparative studies against approved anti-influenza drugs—Oseltamivir, Peramivir, and Baloxivir—NV-387 demonstrated superior antiviral effects. In a lethal lung infection model with the H3N2 strain, NV-387 treated mice showed a remarkable survival rate, significantly outperforming the traditional treatments and highlighting its potential as a more effective antiviral agent.
NV-387 has also shown effectiveness against the orthopoxvirus family through both inhalation and skin abrasion modes of infection acquisition. Notably, Ectromelia virus infection in mice, which is a model for Smallpox in humans and serves as a surrogate for MPox infection, has been successfully countered by NV-387. In a lethal animal model of lung infection by Ectromelia virus, oral administration of NV-387 significantly increased the lifespan of mice, showing comparable results to those treated with tecovirimat, the approved Smallpox drug.
Additionally, NanoViricides is working towards filing a pre-IND at the US FDA for a drug to treat the RSV virus with NV-387, targeted towards underserved adult & pediatric populations.
Its other lead drug candidate is NV-HHV-101 with its first indication as dermal topical cream for the treatment of shingles rash is Phase I-ready.
In summary, the company is Phase II-ready for: RSV, Influenza including Bird Flu H5N1, COVID, MPOX/Smallpox; and has specific drugs in its pipeline for: NV-HHV-1 (VZV Shingles, HSV-1, HSV-2); NV-HIV-1 (HIV/AIDS); and many more.
The achievement of milestones for each drug will likely lead to a further increase in valuation for the company and generate interest from Big Pharma for licensing and co-development partnerships.
